SLU-PP-322

SLU-PP-322 is an experimental small molecule referenced in preclinical metabolic and mitochondrial research.

It does not have established therapeutic indications in routine clinical practice.

Available descriptions suggest that SLU-PP-322 modulates energy expenditure and mitochondrial pathways, but details are based primarily on animal and cell studies.

Discussions around SLU-PP-322 typically center on obesity and metabolic disease models, where it is used as a research tool rather than a standard therapy.

Interventions that increase energy expenditure or alter mitochondrial function can have broad systemic effects, underscoring the need for careful study design.

SLU-PP-322 is in early preclinical development.

The first formulation question here is which compound is in the container. The designation "SLU-PP-322" returns no results in PubMed; the published compound is SLU-PP-332, and searching that name returns a decade of papers from the Burris laboratory. Two digits transposed is a small error with a practical consequence: a certificate of analysis, a supplier listing, and a research paper that do not agree on the compound's name cannot be checked against one another.

SLU-PP-332 is a small molecule, not a peptide, so it does not share the handling logic of the lyophilized peptides it is shelved beside — no reconstitution with bacteriostatic water, no peptide-specific stability considerations. It was characterized specifically as having "sufficient pharmacokinetic properties to be used as an in vivo chemical tool" in mice (Billon et al., ACS Chem. Biol., 2023) — a description of laboratory utility, not of a formulation intended for people.

A related compound, SLU-PP-915, appears alongside it in the cardiac literature (Xu et al., Circulation, 2024). Both remain preclinical chemical tools, and no combination study with any other metabolic agent has been published.

Publications describe SLU-PP-322 in animal models with outcomes related to body weight, adiposity, and metabolic markers, but translation to human disease remains speculative.

For deeper dives on this peptide, see:

• SLU-PP-322 benefits and areas of interest
• SLU-PP-322 side effects and safety context
• SLU-PP-322 dosing concepts (educational)
• SLU-PP-322 research and evidence overview

Is "SLU-PP-322" a real compound? Almost certainly not — it appears to be a transposition of SLU-PP-332. A PubMed search for "SLU-PP-322" returns zero results (checked August 2026), while "SLU-PP-332" returns a published body of work from Thomas Burris and colleagues, originally at Saint Louis University. Anyone researching this compound should search the correct name; anyone buying it should treat a supplier that cannot spell its own product as a data point about that supplier's sourcing.

What is SLU-PP-332? A synthetic agonist of the estrogen-related receptors — a pan agonist hitting ERRα, ERRβ, and ERRγ, with the highest potency at ERRα. ERRs are orphan nuclear receptors with a genetically established role in skeletal-muscle exercise capacity, and the compound was developed specifically because ERRα agonists had been difficult to design (Billon et al., ACS Chem. Biol., 2023). It is a small molecule, not a peptide.

What has it done in animals? In the founding paper it increased mitochondrial function and cellular respiration in a skeletal-muscle cell line, and in mice it increased type IIa oxidative muscle fibers and enhanced running endurance — an effect that disappeared without ERRα, confirming the target (ACS Chem. Biol., 2023). In diet-induced obese and ob/ob mice it raised energy expenditure and fatty acid oxidation, reduced fat mass, and improved insulin sensitivity (Billon et al., J. Pharmacol. Exp. Ther., 2024). Every one of those results is in mice.

Is there anything beyond metabolism? The most substantial paper in this series is cardiac. In a mouse pressure-overload heart-failure model, SLU-PP-332 and the related SLU-PP-915 improved ejection fraction, reduced fibrosis, and increased survival, with genetic dependency experiments showing ERRγ as the mediator (Xu et al., Circulation, 2024). It is careful, well-controlled pharmacology — and still entirely in mice.

Is there any human data? None. No study of SLU-PP-332 or SLU-PP-322 is registered on ClinicalTrials.gov (searched August 2026), and no human safety, pharmacokinetic, or efficacy data have been published. Doses in the mouse work are reported per kilogram of mouse, and rodent milligram-per-kilogram figures do not scale to people.

How does an "exercise mimetic" like this compare with AICAR? Both are small molecules that activate a metabolic program associated with training, and both produced striking mouse endurance results — but they act on different targets. AICAR activates AMPK; SLU-PP-332 activates ERRs. AICAR is the more instructive comparison for a different reason: it did reach large human trials, as acadesine, and failed its primary endpoint (Newman et al., JAMA, 2012). Compelling rodent metabolic data are the entry ticket to human testing, not a prediction of its outcome.